Triple-negative breast cancer (TNBC) is a breast cancer subtype that typically affects younger women, metastasizes early and carries a poor prognosis.1 However, it has a number of characteristics associated with enhanced response to immune checkpoint inhibitors, including increased tumour-infiltrating lymphocytes and programmed death-ligand 1 (PD-L1) expression.2 In 2018, the IMpassion130 clinical trial (ClinicalTrials.gov Identifier: NCT02425891) […]